Novel roles for chemokines and fibroblasts in interstitial fibrosis  by Hogaboam, Cory M. et al.
BASIC SCIENCE - BIOCOMPATIBILITY
Novel roles for chemokines and fibroblasts in interstitial fibrosis
CORY M. HOGABOAM, MATTHEW L. STEINHAUSER, STEPHEN W. CHENSUE, and STEVEN L. KUNKEL
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
Novel roles for chemokines and fibroblasts in interstitial fibrosis.
Background. Regardless of its involvement in either wound
healing or excessive fibrosis, the interstitial fibroblast can now be
considered an important early participant in inflammatory re-
sponses. Although it is recognized that certain immune cells and
proinflammatory mediators are intricately linked to fibrotic dis-
ease, little is presently known about the manner in which these
mediators and cells are orchestrated to a fibrotic finale. Experimental
studies have shown that interstitial fibroblasts are capable of partic-
ipating in an inflammatory response by promoting direct fibroblast-
to-immune cell communication and/or modulating the release of
soluble mediators that are mutually recognized by both types of cells.
Methods. Primary cultures of murine fibroblasts were recovered
from either normal tissue or tissue undergoing a cell-mediated
inflammatory response. These stromal cells were assessed for the
expression of various cytokines and chemokines indicative of a type
1 or type 2 response. In addition, the fibroblasts were co-cultured
with mononuclear cells to assess the cell-to-cell communication.
Results. Fibroblasts recovered from different cell-mediated
inflammatory responses demonstrated a dramatic alteration in
their cytokine profile. Fibroblasts recovered from the type 2
immune response produced high levels of monocyte chemotactic
protein-1 (MCP-1), as compared to the normal fibroblasts and
fibroblasts recovered from the type 1 lesion. Mononuclear cells
co-cultured with fibroblasts induced a contact-dependent expres-
sion of elevated levels of chemokines, especially the macrophage-
derived MIP-1 alpha. Thus, both fibroblasts themselves and
fibroblasts co-cultured with immune-inflammatory cells have the
ability to participate in the maintenance of an inflammatory
response via the expression of chemokines.
Conclusions. Our laboratory and others have addressed the role of
chemotactic cytokines or chemokines in the fibrotic process, and
have demonstrated that fibroblasts are capable of modulating the
activation of various immune cells that have been implicated in
fibrotic disease. In addition, the interstitial fibroblast is capable of
regulating its own behavior within the interstitial environment via the
expression of chemokines and chemokine receptors. Thus, novel
strategies aimed at preventing fibrotic disease will likely need to
address the early engagement of inflammatory cells by fibroblasts,
and possibly modulate the ability of fibroblasts to generate and/or
recognize profibrotic signals supplied by chemokines.
The fibrotic response is a critical component of tissue
restoration or healing following injury or infection. This
process is remarkably complex, involving the co-ordination
of numerous types of cells and a myriad of soluble media-
tors. The quest of researchers in this field has been to
characterize the precise chain of events in the fibrotic
process in order to determine mechanisms through which
this process can be regulated, particularly when it becomes
deleterious as in a number of fibrotic diseases. However,
this task has been incredibly daunting in light of emerging
evidence that the fibrotic process is extremely complex and
appears to be dictated by a variety of biological networks. It
is apparent that excessive fibrosis follows inflammation, but
not all inflammatory events lead to excessive fibrosis. An
inflammatory response to infection or injury within most
tissues is typically characterized by the release of a myriad
of newly generated and preformed inflammatory mediators
by tissue resident immune (that is, macrophages and mast
cells) and non-immune (that is, fibroblasts, epithelial and
smooth muscle) cells. Two key functions of the soluble
mediators are to modulate the function of the resident cells
and promote the infiltration of lymphocytes and phago-
cytes. These concerted efforts ideally facilitate the destruc-
tion and/or clearance of the inflammatory stimulus.
Upon reaching this goal, the final stage of the inflamma-
tory response involves the restoration of the tissue to its
original state. Clearly, the recruitment and tissue reparative
stages must be closely regulated in organs such as the
kidney, gut, lungs, and heart (and presumably the perito-
neal membrane), as excessive tissue injury or over-exuber-
ant tissue healing can severely disrupt the function of these
organs. Whereas the fibroblast is blamed for the complica-
tions of end stage or fibrotic disease, growing experimental
evidence suggest that this tissue resident cell is involved in
the inflammatory process at much earlier stages. For
example, a number of experimental studies now suggest
that interstitial inflammation and homeostasis is achieved,
in part, by counter-regulatory actions of cytokines and
chemokines. Therefore, the nature and consequences of
the interactions between fibroblasts and immune cells such
as macrophages/monocytes, T cells, mast cells, and eosin-
ophils become important aspects of the normal evolution of
the immune response.
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CLINICAL INTERSTITIAL FIBROTIC DISEASES
Interstitial diseases are inflammatory disorders that are
typically characterized by excessive tissue injury and pro-
gressive fibrosis, as exemplified in the pathology of glomer-
ulonephritis, idiopathic fibrosis, and end stage sarcoidosis
[1]. Although a growing list of inflammatory mediators
present in interstitial diseases includes cytokines, growth
factors, prostanoids, eicosanoids and free radicals, little is
currently known about the manner in which these media-
tors initiate and sustain these complex diseases. Clinical
and laboratory evidence suggest that fibrotic diseases result
when the tissue is unable to regulate the inflammatory
process because of the persistence of one or several inflam-
matory signals [2]. Current clinical strategies directed at
preventing fibrotic diseases through the nonspecific inhibi-
tion of the inflammatory process with corticosteroid, cyclo-
phosphamide, and azathioprine treatments have been
largely unsuccessful, and are often associated with severe
side-effects [3]. The failure of the treatment strategies may
relate to the non-discriminating manner in which these
drugs inhibit important modulatory factors involved in the
inflammatory response. Accordingly, recent experimental
data suggest that the development of novel therapeutic
strategies for interstitial fibrotic diseases should encompass
specific modulators of the involvement of the fibroblast in
the inflammatory process. These studies strongly suggest
that the fibroblast is not a bystander during inflammatory
responses in the different involved tissue, but rather has a
very specialized role in the recruitment and regulation of
immune cells that infiltrate the interstitial space. In addi-
tion, the balance between normal tissue repair and excess
collagen deposition appears to be dictated by the nature of
the interaction between immune cells and fibroblasts dur-
ing inflammatory conditions.
DEVELOPMENT OF ANIMAL MODELS OF
INTERSTITIAL FIBROTIC DISEASE
The development of animal models which exhibit persis-
tent cell-mediated immune reactivity has emerged from
observations regarding the participation of cytokines in the
tissue repair stage of the inflammatory process. Interferon-
gamma (IFN-g), although it is a powerful Th1 inducer of
cellular immunity, is a strong inhibitor of the processes
leading to the deposition of extracellular matrix during a
wound healing response [4, 5]. On the opposite end of the
immune spectrum, interleukin-4 (IL-4) is a major Th2
cytokine with potent receptor-mediated activating effects
on fibroblasts [6]. These effects include enhancement of
extracellular matrix generation [7], increased proliferation
and chemotaxis [8]. A unique property of Th1 and Th2
cytokines is that they possess cross-regulatory actions [9],
which appear to ensure that an immune response is appro-
priately balanced to prevent excess tissue injury or repair. It
should be noted that these major classifications of Th cell
cytokines are now commonly referred to as Th1- and
Th2-type cytokines, as it is recognized that cells other than
T cells can generate IFN-g and IL-4 during immune
responses in vivo. For example, natural killer cells are an
important source of IFN-g while mast cells can generate
IL-4 [10]. In addition, macrophage derived IL-12 and IL-10
more recently have been shown to exert prominent cross
regulatory effects on Th cell cytokine profiles, and thus
have also been included in the Th cytokine profiles of
Th1-type and Th2-type, respectively.
With this background knowledge, models of prolonged
pulmonary inflammation were generated that predomi-
nately exhibit either a Th1- or Th2-type cytokine profile
[11]. The intravenous administration of Sephadex beads
coated with purified peptide derivative (PPD) from myco-
bacteria into PPD-sensitized mice initiates the formation of
granulomatous inflammation that is driven by Th1-type
cytokines such as IFN-g, IL-2 and IL-12 [11]. The Th2-type
counterpart to this pulmonary inflammation model in
initiated by the intravenous introduction of the parasite
antigen, Schistosoma mansoni egg antigen (SEA), and this
model is driven by IL-4 and IL-5 [12]. Thus, the nature of
the cytokine profile appears to be critical in the type of
inflammatory cells that are involved in the inflammatory
stage and the magnitude of the tissue reparative stage. The
Th1-type model is typified by the presence of mononuclear
cells such as lymphocytes and monocytes, while the Th2-
type model contains mononuclear cells, fibroblasts, and
eosinophils. The relative importance of IFN-g and IL-4 to
the development and the resolution of granuloma forma-
tion in the respective models was confirmed using adeno-
viral-based gene transfer [13] and gene knock-out mice
[14]. These studies also confirmed that different Th-type
cytokines have cross-regulatory effects in these models of
chronic inflammation; however, it was apparent from these
experiments that other mediators could facilitate the in-
flammatory process in these models in the absence of IL-4
or IFN-g [14].
CHEMOTACTIC CYTOKINES OR CHEMOKINES
The directed migration of inflammatory cells into areas
of inflammation is fueled, in part, by chemotactic proteins
or chemokines. These low molecular weight proteins are
subdivided into a least four expanding families that are
characterized by the juxtaposition of cysteine residues in
the protein’s N-terminus. The C-X-C chemokines were
originally described as neutrophil chemotactic and activat-
ing factors, and examples include IL-8, interferon inducible
protein-10 (IP-10), neutrophil activating protein-2 (NAP-
2), KC, MIP-2 and ENA-78. The C-C chemokine family is
comprised of the macrophage inflammatory proteins
(MIP-1a and MIP-1b), the monocyte chemoattractant pro-
teins (MCP-1,-2, -3, -4, and -5), C10, eotaxin and I-309 [15].
As their names suggest, these chemokines predominately
affect the directional movement of mononuclear cells (that
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is, T cell, monocytes and macrophages), although notable
exceptions include eotaxin, which is a chemoattractant for
eosinophils [16]. The list of C-X-C and C-C chemokines is
far from complete and the use of bioinformatic techniques
has revealed numerous other candidates for these and
other distinct families such as the C and C-X-X-X-C
chemokines [17]. Interestingly, there are now over 40
different ligands related to this supergene family of cyto-
kines. Another intense area of interest in chemokine
biology pertains to the process by which chemokines en-
gage an unique repertoire of G-protein linked cell surface
receptors [18]. The number of receptors for the chemokine
ligands continue to be isolated and identified, as there are
now at least 10 different CCR and 4 unique C-X-C
chemokine receptors. While the families of chemokines
bind to their corresponding chemokine receptors referred
to as the C-x-C chemokine receptors (C-x-CR) and CC
chemokine receptors, within the families there does not
appear to be receptor binding exclusivity. For example, the
chemokine receptor 2 (CCR2) binds a number of C-C
chemokines including MCP-1 through MCP-5.
NOVEL ROLES OF CHEMOKINES IN ANIMAL
MODELS OF FIBROTIC DISEASE
Numerous clinical studies have shown that levels of
C-X-C and CC chemokines are increased at various stages
in interstitial fibrotic diseases. Although the overall contri-
bution of these mediators to the onset or development of
clinical disease has not been thoroughly investigated, a
number of experimental studies suggest that chemokines
may contribute to a number of major events during inter-
stitial fibrosis. Some of these events are described below.
Modulation of cytokine phenotypes
Additional studies using specific models of fibrosis with
defined cytokine phenotypes have revealed that chemo-
kines play a significant immunoregulatory role that is
related, in part, to their effects on the generation of Th1-
and Th2-type cytokines. Neutralization of the CC chemo-
kine, monocyte chemotactic protein-1 (MCP-1), with a
polyclonal rabbit anti-mouse antibody in the Th2-type
model was associated with significantly reduced IL-4 and
IL-5 generation by draining lymph nodes from the area of
inflamed tissue and markedly smaller inflammatory lesions
[19]. Treatment with neutralizing antibody directed against
MCP-1 in the Th1-type model had no effect on cytokine
production or inflammatory lesion size. An additional
interesting observation from this study was that MCP-1 had
a clear inhibitory effect on the ability of isolated peritoneal
macrophages to generate IL-12 following an inflammatory
stimulus [19]. In fact, a number of studies are emerging that
suggest that MCP-1 is intricately involved in the regulation
of Th1- and Th2-type responses. Karpus and co-workers
have shown that T cell activation in the presence of MCP-1
enhances IL-4 generation [20]. Along similar lines we have
demonstrated that MCP-1 directly contributes to the pro-
duction of IL-4 by antigen-activated T cells in a variety of
cell-to-cell interactions [21, 22]. Interestingly, the reduced
lesion size in the Th2-type inflammation model appeared to
be partly related to the reduced levels of extracellular
matrix in these lesions [23].
Angiogenesis
The fibroplasia and deposition of extracellular matrix
associated with fibrotic diseases are partly dependent on
angiogenesis. A number of factors generated during inflam-
mation can precipitate angiogenic responses, but certain
CXC chemokines containing the Glu-Leu-Arg or ELR
motif have recently been shown to exert very potent effects
on neovascularization that are independent of their inflam-
matory effects. Therefore, whereas enhanced IL-8 produc-
tion by macrophages was presumed to lead to the develop-
ment of neutrophilic alveolitis during interstitial fibrosis
[24], more recent studies suggest that IL-8 could be a major
contributor to the neovascularizaton in idiopathic fibrotic
states [25]. Surprisingly, the major source of IL-8 in idio-
pathic fibrosis was the interstitial fibroblast [25]. This study
also suggested that an ambitious angiogenic response dur-
ing fibrotic disease was a consequence of enhanced angio-
genic levels of IL-8 and decreased levels of angiostatic
IP-10. IP-10 is a non-ELR containing CXC chemokine
produced by a number of cells following activation with
IFN-g. Further studies are underway to determine the
relative role of angiogenic CXC chemokines during fibrotic
responses.
Chemoattraction of immune cells putatively involved
in fibrosis
Several chemokines have emerged as important che-
moattractants during clinical and experimental fibrotic
disease. The chemokine “regulated on activation, normal T
cell expressed and secreted” (RANTES) is a potent che-
moattractant for T cells and eosinophils, and is markedly
elevated in interstitial fibrosis [26]. Little is currently known
about the role of RANTES in the interstitial fibrotic
process. MCP-1 and MIP-1a are also abundantly expressed
during many stages of interstitial fibrotic disease [27–29]. In
addition to macrophages, epithelial cells and smooth mus-
cle cells, fibroblasts isolated from patients with idiopathic
fibrosis exhibit enhanced MCP-1 and MIP-1a generation
[28]. Experimental models of fibrosis in the lung [30, 31]
and kidney [32] are also characterized by increased MCP-1
and MIP-1a generation. The role of MIP-1a has been
examined in a bleomycin model of pulmonary fibrosis, and
it appears that it exerts a prominent role in the recruitment
of mononuclear and polymorphonuclear cells to the lung
[33]. Immunoneutralization of MCP-1 in a bleomycin
model of lung fibrosis resulted in an approximately 30%
reduction in the number of recruited mononuclear cells
[33]. In studies examining the development of fibrosis
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during experimental crescentic nephritis, Lloyd et al used
immunoneutralization techniques to demonstrate that
MCP-1, but not RANTES or MIP-1a, contributes to
crescent formation and renal fibrosis (that is, type I pro-
collagen deposition) [32]. However, the role of MCP-1 in
the renal fibrotic response in this model could not be
entirely defined by the effect of MCP-1 on the recruitment
of T cells and macrophages to the inflamed glomerulus
[32].
Augmented collagen generation by fibroblasts
Another putative explanation for the findings presented
by Lloyd et al [32] is derived from recent studies by
Gharaee-Kermani, Denholm and Phan [34], who have
shown that MCP-1 indirectly contributes to de novo colla-
gen production by fibroblasts. MCP-1-activated fibroblasts
markedly increased transforming growth factor-b (TGF-b)
production, which in turn was the major effector molecule
in the induction of type I collagen in these fibroblasts [34].
TGF-b is one of the most potent profibrotic cytokines yet
described [35]. Whereas targeting TGF-b in fibrotic re-
sponses may be fraught with serious problems similar to
those observed in TGF-b gene disruption studies [36],
modulation of MCP-1 production during interstitial fibrotic
responses may provide a viable treatment option in inter-
stitial fibrotic disease. Thus, these studies, as in the studies
assessing glomerulonephritis, suggest that C-C chemokines
not only recruit immune cells that generate profibrotic
mediators, but are also involved in the direct activation of
the fibroblast leading to extracellular matrix generation.
INTERSTITIAL FIBROBLASTS ARE A DYNAMIC
SOURCE OF CHEMOKINE GENERATION
Chemokines and their respective receptors were primar-
ily considered to be the products of immune cells, but the
literature now strongly suggests otherwise [37]. The fibro-
blast is among the many non-immune cells that readily
generate chemokines and express chemokine receptors
following cytokine activation. Fibroblasts from many tissue
sites (including the peritoneal cavity) and species are a
major source of constitutive and cytokine-induced C-C and
C-X-C chemokines such as MCP-1, MIP-1a, RANTES,
IP-10, KC and eotaxin [38]. Xia and colleagues have
recently supplied very interesting data that suggests that
fibroblasts are differently regulated in their chemokine
generation than bone-marrow-derived cells [39]. An impor-
tant regulator of chemokine production by fibroblasts
appears to be RelB, a transcription factor that is rapidly
increased following the activation of fibroblasts with in-
flammatory stimuli such as IL-1b, TNFa and LPS. In the
absence of RelB expression in fibroblasts, but not in
macrophages, NF-kB activity remains unchecked and che-
mokine generation continues unabated. Interestingly, RelB
knock-out mice exhibit a syndrome of multi-organ inflam-
mation characterized by a predominant interstitial infiltrate
of neutrophils, monocytes and macrophages [39]. Other
interesting findings regarding fibroblasts pertain to their
regulation of chemokine receptor expression. Recent stud-
ies in this laboratory demonstrate that fibroblasts cultured
from a fibrotic lesions have markedly elevated expression of
CCR2 compared to fibroblasts cultured from non-fibrotic
lesions. These findings are of potential therapeutic signifi-
cance, since it may be possible to selectively inhibit the
fibroblast from generating or responding to a number of
chemokines that appear to be directly involved in the
interstitial fibrotic process.
INTERSTITIAL FIBROBLASTS CAN ENGAGE
INFLAMMATORY AND IMMUNE CELLS
The recruitment of inflammatory and immune cells such
as monocytes, T cells, mast cells and eosinophils into the
interstitial space presumably represents an important initial
step in the cascade of events leading to end-stage fibrosis.
Numerous studies now indicate that these recruited cells
are activated and/or regulated in a fashion that is depen-
dent upon their interactions with tissue resident cells such
as the fibroblast. Below are examples of cell-to-cell inter-
actions that are postulated to be involved in sustaining
inflammatory or immune events that ultimately lead to
inappropriate tissue repair.
Macrophages and recruited monocytes
These cells appear to have a central role in the initiation
and exacerbation of inflammatory tissue injury, and are
hypothesized to be responsible for the eventual develop-
ment of various types of idiopathic fibrosis [1]. Macro-
phages are among the first immune cells found in increased
numbers at the early stages of fibrosis, and because these
resident cells are uniquely situated within the interstitum,
their released mediators activate numerous structural cell
types including epithelial cells, smooth muscle cells and
fibroblasts. Platelet-derived growth factor was one of the
first profibrotic mediators identified to be spontaneously
released by macrophages in patients with fibrotic disease
[40, 41]. Macrophages may further contribute to tissue
injury through their synthesis of IL-8. One putative mech-
anism for sustained IL-8 production in fibrosis may relate
to the destructive effect of activated neutrophils on the
matrix components of the tissue interstitum. Although this
process is necessary in normal tissue regeneration or heal-
ing responses, in fibrosis it appears that hyaluronan frag-
ments of extracellular matrix may exacerbate or maintain
the production of IL-8 by macrophages through a CD44-
dependent mechanism [42, 43]. As explained above, IL-8
may also play a major role in the angiogenic response
during tissue fibrosis. Additional immunohistochemical ev-
idence suggests that the lung fibroblast may also contribute
to the changes in PDGF and IL-8 levels in idiopathic
pulmonary fibrosis (IPF) [25], but whether these changes in
the synthetic capacity of the fibroblast are related to direct
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interactions between these cells and alveolar macrophages
has yet to be determined.
The increased trafficking of monocytes into the inflamed
pulmonary interstitum during IPF is presumed to occur, in
part, through the increased production of C-C chemokines
such MIP-1a. As mentioned earlier, MIP-1a levels are
increased in IPF due to the exaggerated production of this
mediator by alveolar macrophages and epithelial cells [29].
We have examined the role of fibroblasts in the generation
of MIP-1a by a macrophage cell line (Raw 264.7) in a
cell-to-cell co-culture system. MIP-1a production by the
co-cultured macrophages was markedly elevated after one
hour of direct contact between these cells and lung fibro-
blasts. Direct contact between these cells was required for
MIP-1a generation by macrophages since the transwell
separation of these cells inhibited this response (Fig. 1).
Further experiments revealed that MIP-1a production was
dependent upon the TNFa-induced expression of ICAM-1
by the fibroblast [44]. Taken together, these data suggest
that the interaction between fibroblasts and macrophages
may be an important early event in the recruitment of
monocytes and may facilitate a cytokine network that
maintains the activation of tissue resident alveolar macro-
phages.
T cells
Chronological analysis of cells present in the tissue from
patients with fibrosis indicated that there was an initial
infiltration of different T helper cells [45]. Th2 cells can
modulate the proliferation and biosynthetic capacity of
fibroblasts [46], largely because of their ability to generate
IL-4, which will recognize specific receptors expressed by
fibroblasts [6], cause these cells to proliferate [47] and to
undergo directed movement toward inflammatory stimuli
[8]. IL-4 activation of fibroblasts also promotes the biogen-
esis of extracellular matrix proteins in normal repair pro-
cesses and during pathologic fibrotic responses in which T
cells are involved [7]. However, the interaction between T
cells and fibroblasts is not unidirectional. Rather, there is
emerging evidence that the fibroblast can modulate the
activation state of T cells. Bombara et al have shown that
direct contact between T cells and fibroblasts promotes the
induction of adhesion molecules and cytokine production
by the T cells [48]. Other studies have shown MCP-1
induced binding of T cells to fibronectin and endothelium-
derived extracellular matrix through the activation of
VLA-4 and-5 on the T cell surface. Interestingly, MCP-1
did not augment T cell interactions with ICAM-1 or
vascular cell adhesion molecule-1 (VCAM-1) [49]. In stud-
ies conducted in our laboratory, the generation of MCP-1
by untreated and cytokine-pretreated fibroblasts was nec-
essary for the generation of IL-4 by antigen-rechallenged
CD41 T cells. This effect was demonstrated through both
the specific immunoneutralization of MCP-1 using a poly-
clonal antibody and the inhibition of MCP-1 synthesis using
MCP-1 antisense oligonucleotides [22]. However, the ab-
sence of MCP-1 during the co-culture of CD41 T cells and
fibroblasts was also associated with significantly enhanced
CD41 T cell proliferation. Thus, the data at present
suggests that bi-directional interactions between T cells and
fibroblasts presumably serve to modulate the activity of
both cells. MCP-1 regulation of T cells during chronic
inflammatory responses may have great implications for the
progression of interstitial fibrosis.
Mast cells
Mast cell numbers and histamine levels have been shown
to be increased in samples taken from patients with fibrosis
[50]. As in the case of T cells, mast cells are found in fibrotic
lesions [35, 51], but the exact role of this tissue resident cell
is unknown. Recent data suggest that mast cells may have a
deleterious role to play in the fibrotic process. In particular,
interactions between mast cells and fibroblasts facilitates
the de novo production of eotaxin, a potent eosinophil
chemattractant [16, 52, 53]. In normal fibroblasts, eotaxin
production approaching 1 ng/ml could be detected follow-
ing exposure of these cells to IL-4, but not TNFa or IFN-g,
for 24 hours. However, the highest production of eotaxin
was observed in 24 hour co-cultures of mast cells and
untreated fibroblasts. In this system, mast cells and fibro-
blasts cultured alone produced , 100 pg/ml of eotaxin, but
in combination these cells generated levels of eotaxin
exceeding 20 ng/ml. Interestingly, the expression of eotaxin
in the co-culture system was detected in both cell types, and
was dependent upon the cell surface expression of stem cell
factor by the fibroblast. Thus, these recent findings supply
Fig. 1. Macrophage/fibroblast co-culture induces contact-dependent
MIP-1a production. Primary peritoneal macrophage (PM) cultures
(100,000/well) were layered onto a primary lung fibroblast (F) monolayer.
Peritoneal macrophage controls were layered onto a fixed fibroblast
(FIXED F) monolayer (10 min with 4% paraformaldehyde). In the F 1
PM(TW) group, the two cell populations were physically separated by a
membrane which allows the passage of culture media plus any soluble
factors. MIP-1a concentrations were evaluated by ELISA after 24 hours of
co-incubation and expressed as mean 1 SE. N 5 3 to 6. MIP-1a was only
detected in co-cultures containing F 1 PM. * P , 0.05.
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evidence that lung fibroblasts, via its expression of a cell
surface ligand that mast cells recognize, can enhance the
expression of a potent chemoattractant for eosinophils.
Eosinophils
Eosinophils have only recently been identified as culprits
in fibrotic responses in the lung [54–56] and it is generally
recognized that eosinophilia is present in many disorders
characterized by tissue fibrosis [57, 58]. A strong associa-
tion between the presence of eosinophils in tissue and a
poor disease prognosis or a resistance to anti-inflammatory
therapy is now recognized in fibrotic disease, especially
interstitial pulmonary diseases [57]. Experimental fibrosis
induced via bleomycin is also associated with profound
eosinophil infiltration [31] and a direct role for eosinophils
in the fibrotic process [59]. These observations have
spawned numerous studies examining the nature of the
interaction between fibroblasts and eosinophils. Eosino-
phils readily bind to fibroblasts and many studies have
shown that this leads to the release of mitogens that
augment fibroblasts proliferation [60] and collagen produc-
tion [61]. For example, eosinophils appear to be a major
source of MCP-1 and TGF-b during the later proliferative
stages of the bleomycin fibrosis model [31, 33]. There is also
abundant evidence that the interaction between fibroblasts
and eosinophils is bi-directional, since the survival of
eosinophils appears to be dependent on the lung fibroblast
through its production of granulocyte macrophage-colony
stimulating factor [62]. Thus, the findings currently point to
a mutual interaction between eosinophils and fibroblasts
that has the potential to recapitulate their interactions
through the sustained activation of eosinophils and the
activation of the lung fibroblast to that of a biosynthetic
cell.
CONCLUSIONS
Previously, the fibroblast was considered to be a passive
participant in the fibrotic process through its end stage
contribution of extracellular matrix. However, emerging
evidence from many laboratories now points to a more
active role for fibroblasts in the inflammatory process
leading up to end stage disease. In the context of the
peritoneal cavity interstitial fibroblast activation may play a
key role in peritoneal inflammatory processes and thus
might contribute to the development of peritoneal fibrosis
[63, 64]. Similarly, pulmonary fibroblasts are capable of
generating a number of chemokines that are directly or
indirectly involved in the fibrotic process, such as IL-8,
RANTES, MCP-1 and MIP-1a. In addition, fibroblasts are
uniquely positioned and are capable of modulating T cell
lymphokine generation, mast cell activation leading to the
elaboration of the eosinophil chemoattractant eotaxin, and
activation of eosinophils by producing eosinophil survival
factors. Given the numerous ways in which the fibroblast
may be involved in many aspects of immune activation and
modulation in the lung interstitum, it would certainly seem
that it is an ideal target in the treatment of fibrotic diseases.
Selective regulation of the chemokine synthetic capacity of
the fibroblast is certainly feasible in light of recent obser-
vations that chemokine generation in fibroblasts is regu-
lated differently from immune cells such as macrophages.
While the precise clinical contribution of chemokines to the
fibrotic process needs further exploration, the modulation
of chemokine production and/or binding of these mediators
to chemokine receptors may supply some novel therapeutic
alternatives in the treatment of interstitial fibrosis not only
in the lung, but elsewhere.
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